Table 3.

Factors associated with DM control in diabetic DC Cohort participants with an A1C measurement from April 1, 2017 to March 31, 2018 (N=408)

	OR (95% CI), p-value	aORa (95% CI), p-value
Variable Category
Age (per 5 years)	0.91 (0.82, 1.02), 0.11	0.94 (0.81, 1.09), 0.43
Sex at birth
Female	1.10 (0.70, 1.73), 0.69	1.01 (0.58, 1.78), 0.96
Race
Race other than Non-Hispanic Black (compared with Non-Hispanic Black)b	1.48 (0.84, 2.60), 0.17	0.98 (0.51, 1.90), 0.95
BMI
≥ 30 kg/m2	0.66 (0.44, 0.99), 0.04	0.47 (0.28, 0.79), 0.005
Clinic type
Community-based	1.56 (1.04, 2.33), 0.03	1.30 (0.78, 2.16), 0.32
Diabetes diagnosis present at DC cohort consent	0.25 (0.16, 0.39), <0.0001	0.31(0.19, 0.52), <0.0001
Diabetes medication use
No medication	Ref	Ref
Non-insulin medication only	0.42 (0.26, 0.69), 0.0006	0.43(0.25, 0.73), 0.002
Insulin only	0.09 (0.04, 0.22), <0.0001	0.10(0.04, 0.24), <0.0001
Both insulin and non-insulin medication	0.08 (0.04, 0.17), <0.0001	0.08(0.03,0.17), <0.0001
On PI*
Yes	1.46 (0.94, 2.29), 0.09	1.62 (0.94, 2.80), 0.08
HCV Comorbidity
Yes	1.44 (0.82, 2.53), 0.21	1.93 (0.97, 3.86), 0.06
Insurance status (baseline)
Private/Other/Unknownc	1.44 (0.80, 2.58), 0.23	1.00 (0.50, 2.02), 1.00

Abbreviations: DM: Diabetes mellitus; aOR: adjusted Odds Ratio; HCV: Hepatitis C virus. PI: protease inhibitor.

^*At time of HbA1c measurement

^aAdjusted for age, sex at birth, race, BMI, clinic type, diabetes medication, insulin, current PI use, HCV comorbidity, and insurance status

^bCategory includes NH White, Hispanic, mixed race, Asians, Alaska Natives, American Indians, Hawaiians, Pacific Islanders, and unknown race.

^cReferent category is public insurance.